AbbVie JAK inhibitors have been approved to treat psoriasis arthritis and severe spina blinitis

Psoriasis arthritis is a systemic inflammatory disease with symptoms in multiple parts of the body.
inflammation of the immune system in patients with psoriasis arthritis, which can lead to skin lesions, joint pain, fatigue and stiffness associated with psoriasis.
is a chronic, inflammatory musculoskeletal disease that mainly affects the spine and is characterized by debilitating symptoms such as pain, limited mobility and structural impairment.
progress has been made in treating both diseases, many patients' symptoms are not being alleviated enough.
Rinvoq is a daily oral JAK1 selective small molecule inhibitor.
previously, the FDA had approved its listing for the treatment of adult patients with moderate to severe active rheumatoid arthritis.
addition, it conducts clinical studies in several other inflammatory adaptations, including Crohn's disease, ulcerative colitis, and endexual dermatitis.
approvals were supported by three clinical trial results.
in two Phase 3 clinical trials, SELECT-PsA1 and SELECT-PsA2, Rinvoq reached the primary endpoint in adult patients with active psoriasis arthritis with poor DMARD efficacy.
ACR20 response improved significantly in week 12 compared to placebo.
Rinvoq also meets non-inferior standards compared to the common therapy Adamo monoantigen.
patients treated with Rinvoq also showed greater improvement in physical function and skin symptoms than the placebo group.
in phase 2/3 clinical trial SELECT-AXIS1, Rinvoq was used to treat adult patients with severe spina brysitis who had not been treated with the biological product DMARD.
results showed that Rinvoq reached the primary endpoint, significantly improving the patient's Spinal Arthritis International Association (ASAS) 40 response assessment compared to a placebo.
" psoriasis arthritis and strong spina blinitis have a significant impact on many aspects of a patient's life.
" said Dr. Tom Hudson, AbbVie's Chief Scientific Officer and Senior Vice President of Research and Development, "We are proud to offer a new treatment option for people with psoriasis arthritis, as well as a 'first-in-class' treatment option for patients with strong spina blanditis."
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
references: s1 .™ . Retrieved January 25, 2021, from